Promega

pmirGLO Dual Luciferase miRNA

Varenummer: E1330
Kort informasjon 20 µg
  • Produktinformasjon
  • Relaterte produkter
  • Alternative produkter
  • Spesifikasjoner
The pmirGLO Vector is designed to quantitatively evaluate microRNA (miRNA) activity by the insertion of miRNA target sites downstream or 3' of the firefly luciferase gene (luc2). Firefly luciferase is the primary reporter gene; reduced firefly luciferase expression indicates the binding of endogenous or introduced miRNAs to the cloned miRNA target sequence. This vector is based on Promega dual-luciferase technology, with luc2 used as the primary reporter to monitor mRNA regulation and Renilla luciferase (hRluc-neo) acting as a control reporter for normalization and selection.|

Measure miRNA Function: Reporter activity correlates with miRNA activity.
Optimized Reporter Genes: luc2 gene provides highest expression.
Combination Renilla/Neomycin Marker: Normalize with Dual-Luciferase(R), Assay or for stable cell lines, all with one vector.
Biologically Relevant Results: The moderate-strength PGK promoter provides sensitive analysis not possible with strong promoters.

Det finnes ingen relaterte produkter.

Det finnes ingen alternative produkter.
Ekstra spesifikasjoner
Store at -20°C.|BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the researcher is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the researcher with a full refund.Researchers may use this product for research use only, no commercial use is allowed. Commercial Use means any and all uses of this product and derivatives by a party for monetary or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that Researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, Researchers must either: (1) use luminescent assay reagents purchased from Promega Corporation for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA. The above license relates to Promega patents and/or patent applications on improvements to the luciferase gene.European Pat. No. 1341808 and other patents and patents pending.The method of recombinant expression of Coleoptera luciferase is covered by U.S. Pat. Nos. 5,583,024, 5,674,713 and 5,700,673. A license (from Promega for research reagent products and from The Regents of the University of California for all other fields) is needed for any commercial sale of nucleic acid contained within or derived from this product.

Kontaktperson(er) til dette produktet

Christine Rindal Ibra 944 34 009 christine.rindal.ibra@nmas.no
Claudia Emmanuel 951 51 950 claudia.emmanuel@nmas.no
Monica Laukas 404 40 960 monica.laukas@nmas.no

Kontakt oss

Ønsker du mer informasjon om våre produkter eller tjenester?
Fyll inn dine kontaktopplysninger og hva saken gjelder, så tar vi kontakt med deg.

Kontaktskjema
Bedrift
Telefon
E-post
Melding